# Royalty Pharma plc Class A Ordinary Shares (RPRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $63.96, market value $37.0 billion.

## Valuation
- **P/E (trailing): 34.4×** (5-yr avg 85.9×, 3-yr avg 14.9×). Royalty Pharma plc Class A Ordinary Shares trades at 34.4× trailing earnings, well below its own five-year average of 85.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 11.1×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 14.6×**. Each dollar of revenue is priced at 14.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.2×**. The shares trade at 4.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 29.9×**. Enterprise value is 29.9× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Earnings yield: 2.9%**. The inverse of the P/E: 2.9% of the price is earned each year.

## Profitability
- **Operating margin: 59.6%**. 59.6% of revenue is left after running the business, an exceptional level.
- **Net margin: 32.4%**. 32.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 7.9%**. 7.9% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 6.6%**. Return on all capital, debt included, is 6.6%.
- **Return on assets: 4.1%**. Each dollar of assets produces 4.1% of profit.

## Growth
- **Revenue growth (1 yr): 5.1%** (3-yr 2.1%/yr, 5-yr 2.3%/yr). Revenue grew 5.1% over the last year, against 2.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -6.8%** (3-yr 161.1%/yr, 5-yr 6.2%/yr). Earnings per share fell 6.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.92**. Debt is 0.92 times equity, moderate leverage.
- **Net debt / EBITDA: 5.5×**. It would take 5.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 3.32**. A Z-score of 3.32 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 1.47%** ($0.91 per share, trailing). Royalty Pharma plc Class A Ordinary Shares yields 1.47%, a modest yield more typical of a growth-oriented payer.
- **Consecutive years of increases: 6**. 6 straight years of increases.
- **Dividend growth (5 yr): 24.0%/yr** (1-yr 4.8%). The dividend has compounded at 24.0% a year over five years, doubling roughly every 3 years at that pace.

## Price and momentum
- **Total return (1 yr): 76.0%** (YTD 67.1%, 3-mo 14.5%). The shares are up 76.0% over twelve months including dividends.
- **From 52-week high: -0.7%** (84.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 70**. An RSI of 70 is neutral.
- **Beta (1 yr): 0.25** (volatility 23%). Beta of 0.25 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RPRX · Page: https://foliofundamentals.com/stocks/rprx

Not investment advice.